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O B J E C T I V E S The goal of this study was to evaluate whether individuals with a positive family
history for premature coronary artery disease (CAD) and coronary calcium scoring (CCS) above the 80th
percentile might beneﬁt from preventive treatment.
B A C KG ROUND First-degree relatives of patients with premature CAD have an increased risk for
cardiovascular disease (CVD), whereas events are poorly predicted in these individuals. Surrogate
markers, such as CCS, might reﬁne risk scoring. Nevertheless, the outcome of the St. Francis Heart trial,
which investigated the effect of atorvastatin 20 mg/day in asymptomatic individuals with CCS above the
80th percentile, did not reach statistical signiﬁcance.
METHOD S We performed a post hoc analysis on the database of the St. Francis trial to assess
efﬁcacy of treatment with atorvastatin 20 mg/day in those with CCS above the 80th percentile and
presence (n  543) or absence (n  462) of a positive family history for premature CAD. All participants
received aspirin 81 mg/day. Primary outcome included coronary death, myocardial infarction, coronary
revascularization, stroke, and arterial surgery.
R E S U L T S A total of 1,005 individuals, with a mean age of 59.0  5.9 years and a median absolute
CCS of 370 Agatston units (interquartile range: 183 to 662) participated in the trial. After a follow-up of
4.3 (interquartile range: 3.5 to 4.5) years, 7.2% of the treated individuals with a positive family history had
a cardiovascular event versus 12.5% of the placebo group (hazard ratio [HR]: 0.55; 95% conﬁdence
intervals [CI]: 0.31 to 0.97; p  0.040). This is comparable with a number needed to treat of 18.9. In
individuals without a family history, events were minimally reduced: 6.6% in the treated versus 6.8% in
the placebo group (HR: 1.04; 95% CI: 0.51 to 2.13; p  0.912).
CONC L U S I O N S The combination of a positive family history and CCS above the 80th percentile
identiﬁes a subgroup within the primary prevention population that receives greater beneﬁt from statin
treatment than the population at large. These results have important implications for future guidelines
concerning individuals with a positive family history for premature CAD. (J Am Coll Cardiol Img 2012;
5:252–60) © 2012 by the American College of Cardiology Foundation
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253positive family history for premature coronary
artery disease (CAD) is an independent risk
factor for cardiovascular disease (CVD)
(1–4). The associated risk increases fur-
ther when relatives are affected at a younger age,
with an odds ratio (OR) of 1.3 in individuals with
relatives affected below 55 years, to ORs of 10 and
higher in individuals with relatives affected below
45 years of age (5–7).
However, if we assume an important and
(co)dominant hereditary component, not all rela-
tives will be exposed to the same risk. This empha-
sizes the need to further refine the risk assessment
See page 261
among siblings in these families. Traditional risk
algorithms poorly predict cardiovascular risk in
general, but even more so in relatives of patients
with premature CAD (8). This is mainly due to the
fact that the question of risk mostly arises at a time
when individuals are still young, whereas age is the
most important risk predictor for CVD per se.
Therefore, novel tools are continually developed
to better indentify subclinical disease in asymptom-
atic individuals.
Coronary calcium score (CCS) has emerged as an
interesting tool in the cardiovascular arena, since it
can measure the severity of subclinical CAD, cor-
relates well with plaque burden in pathology stud-
ies, and can predict cardiovascular events indepen-
dent of other risk factors (9–13).
In both the American College of Cardiology
Foundation/American Heart Association 2010
Guideline for Assessment of Cardiovascular Risk in
Asymptomatic Adults and the Appropriate Use
Criteria for Cardiac Computed Tomography, it is
expressed that measurement of CCS is a reasonable
method for cardiovascular risk assessment in
asymptomatic adults at intermediate risk (14,15). In
the Appropriate Use Criteria for Cardiac Com-
puted Tomography, it was even stated that it is
appropriate for individuals at low risk in whom a
family history of premature CAD is present.
However, to date, there is no evidence that
treatment of such in individuals has any benefit in a
primary prevention setting as recently mentioned by
the Working Group on Nuclear Cardiology and
Cardiac Computed Tomography (CT) of the Eu-
ropean Society of Cardiology (16). In fact, the only
randomized controlled trial (RCT), the St. Francis
Heart study, comparing treatment versus placebos
in asymptomatic individuals with CCS above the80th percentile, showed a 33% reduction in events,
which failed to meet accepted levels of statistical
significance (17).
In view of the clear predictive value of a positive
family history, we hypothesized that individuals
with both a positive family history for premature
CAD and elevated CCS in the St. Francis Heart
study represent a high-risk population that might
have benefited from treatment.
To test this hypothesis, we performed a post hoc
analysis on the database of the St. Francis Heart
study, and we compared treatment with atorvastatin
20 mg, aspirin 81 mg, vitamin C 1 g, and vitamin E
1,000 U with aspirin 81 mg and matching placebo
in individuals with a CCS score above the 80th
percentile, stratified to either the presence or ab-
sence of a positive family history for premature
CAD.
M E T H O D S
Study individuals and design. The study
design of the St. Francis Heart study RCT
was previously reported (18). In brief,
recruitment began in February 1996. Ap-
proximately 300,000 recruitment letters
and questionnaires were sent to residents
of Nassau and Queens counties in New
York state. About 20,000 questionnaires
were returned and screened for exclusion
criteria. Men and women 50 to 70 years-
of-age were considered eligible for this
study, provided they had no history, no
symptoms (Rose questionnaire) (19), or
no signs of any cardiovascular disease. Furthermore,
individuals were excluded if they had insulin-
dependent diabetes mellitus or if they used any
lipid-lowering drugs.
After this, 5,582 subjects who met the inclusion
criteria and signed informed consent were scanned
with electron beam CT. CT scanning was per-
formed at enrollment with reconstruction to a
26-cm field of view. Forty contiguous 3-mm slices
were scanned during a single breath hold. Scan time
was 100 ms/slice, synchronized to 80% of the RR
interval. At least 2 adjacent pixels with an attenu-
ation coefficient 130 Hounsfield units defined a
calcified lesion, and CCS was calculated according
to Agatston et al. (20).
Individuals with CCS above the 80th percentile
for age and gender, as defined by an internal
database comprising more than 5,000 asymptom-
A B B
A N D
CAD
CCS
CI c
CT
CVD
HR
LDL
OR
RCT
controatic persons, were invited to participate in theR E V I A T I O N S
A C R O N YM S
coronary artery disease
coronary calcium score
onfidence interval
computed tomography
cardiovascular disease
hazard ratio
low-density lipoprotein
odds ratio
randomizedRCT.
ranges; LDL  low-density
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254Individuals were randomized into 2 parallel
groups, the first receiving atorvastatin 20 mg daily,
vitamin C 1 g daily, and vitamin E (alpha tocoph-
erol) 1,000 U daily (from now on called treated
group) versus matching placebos (from now on
called placebo group), administered in double-blind
fashion. In addition, all participants were given 81
mg of aspirin daily. Study participants experiencing
nonfatal coronary outcomes who met either 4S
(Scandinavian Simvastatin Survival Study) (21) or
CARE (Cholesterol and Recurrent Events) (22)
criteria were placed on open-label atorvastatin 20
mg daily. Compliance, defined as consumption of at
least 85% of study medications, was assessed by pill
counts every 3 months.
acteristics of Individuals With a Positive and a Negative Family H
Positive Family History
Placebo
(n  280)
Treated
(n  263) All (n  543
58.4 5.9 58.9 5.8 58.7 5.9
205 (73.2) 182 (69.2) 387 (71.3)
187 (66.8) 165 (62.7) 352 (64.8)
llitus 24 (8.6) 19 (7.2) 43 (7.9)
n 96 (34.2) 92 (35.0) 188 (34.6)*
29.3 5.0 29.1 5.0 29.3 5.0
137.4 19.0 135.9 20.9 136.7 19.9
79.6 9.3 79.0 9.9 79.3 9.6
l/l 5.9 0.9 6.0 0.9 5.9 0.9*
/l 3.9 0.8 3.9 0.8 3.9 0.8*
l/l 1.3 0.4 1.3 0.4 1.3 0.4
1.5 (1.0, 2.1)† 1.3 (0.9, 2.0) 1.3 (0.9, 2.0)
6.2 1.8 6.1 1.5 6.2 1.8
/l 2.12 (1.08, 4.07) 1.74 (0.94, 3.96) 1.90 (0.98, 3.9
11.9 (7.6, 16.9) 11.0 (7.2, 16.2) 11.3 (7.4, 16.6
107 (38.2) 116 (44.1) 223 (41.1)
139 (49.6) 112 (42.6) 251 (46.2)
34 (12.1) 35 (13.3) 69 (12.7)
360.5 (177.1, 627.0) 354.8 (179.5, 626.6) 358.7 (178.7, 62
25 (8.9) 26 (9.9) 51 (9.4)
16 (5.7) 20 (7.6) 36 (6.6)
15 (5.4) 18 (6.8) 33 (6.1)
22 (7.9) 13 (4.9) 35 (6.4)
rugs 16 (5.7) 20 (7.6) 36 (6.6)
16 (5.7) 12 (4.5) 28 (5.2)
ol/l 5.33 1.02† 4.34 0.86 4.81 1.06
ol/l 3.36 0.76† 2.44 0.72 2.87 0.87
an  SD except for CRP, Framingham score, and calcium score, which are express
e family history, †p  0.05 versus treated.
BP  blood pressure; CAD  coronary artery disease; CRP  C-reactive protein; D
lipoprotein; SBP  systolic blood pressure.Primary outcome included all cardiovascular
events, which were verified by an independent
committee of current or former coronary care unit
directors at academic medical centers, blinded to
the CCS and treatment assignment. Cardiovascular
events included coronary death, nonfatal myocardial
infarction, surgical or percutaneous coronary revas-
cularization procedures, nonhemorrhagic stroke,
and peripheral vascular (i.e., arterial) surgery. Only
the first event experienced by a patient was re-
corded. We calculated the effect of all different
composites of the primary outcome with Cox pro-
portional hazards analyses.
Secondary outcomes included all coronary events,
which included nonfatal myocardial infarction, cor-
ry for Premature CAD, Divided by Treatment
Negative Family History
Placebo
(n  236)
Treated
(n  226) All (n  462)
59.5 6.1 59.2 6.0 59.4 6.0
177 (75.0) 177 (78.3) 354 (76.6)
158 (66.9) 164 (72.6) 322 (69.7)
15 (6.4) 16 (7.1) 31 (6.7)
68 (28.8) 57 (25.2) 125 (27.1)
29.2 5.1 29.9 4.9 29.5 5.0
136.1 19.1 136.0 16.7 136.0 17.9
79.0 9.0 78.9 8.4 78.9 8.7
5.8 0.9 5.6 0.9 5.7 0.9
3.8 0.7 3.6 0.8 3.7 0.8
1.3 0.4 1.3 0.4 1.3 0.4
1.4 (1.0, 2.0) 1.3 (0.8, 2.0) 1.3 (0.9, 2.0)
6.2 1.4 6.2 1.9 6.2 1.7
2.10 (0.87, 5.02) 2.63 (0.98, 4.47) 2.26 (0.93, 4.61)
10.5 (7.1, 17.0) 10.6 (7.3, 15.7) 10.6 (7.2, 16.2)
112 (47.5) 97 (42.9) 209 (45.2)
85 (36.0)† 111 (49.1) 196 (42.4)
39 (16.5)† 18 (8.0) 57 (12.3)
395.7 (188.3, 747.7) 396.8 (186.2, 659.1) 396.3 (187.5, 690.7)
18 (7.6) 11 (4.9) 29 (6.3)
16 (6.8) 19 (8.4) 35 (7.6)
12 (5.1) 12 (5.3) 24 (5.2)
11 (4.7) 15 (6.6) 26 (5.6)
14 (5.9) 17 (7.5) 31 (6.7)
9 (3.8) 6 (2.7) 15 (3.2)
5.38 0.97† 4.20 0.80 4.83 1.07
3.35 0.82† 2.28 0.65 2.85 0.92
median (25th, 75th percentiles), categorical values are n (%). *p  0.05 versus
diastolic blood pressure; HDL  high-density lipoprotein; IQR  interquartileTable 1. Patient Char isto
)
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History of smoking
History of diabetes me
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BMI, kg/m2
SBP, mm Hg
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LDL cholesterol, mmol
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Framingham risk score
Median )
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Intermediate risk
High risk
Baseline calcium score 6.4)
Medication use
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255onary death, and surgical or percutaneous coronary
revascularization procedures, and all events occur-
ring 90 days after randomization. The latter was
hosen since early events (e.g., before 90 days)
ight not have been influenced by the treatment
rotocol.
Furthermore, we calculated the effect of treat-
ent, excluding individuals with a high Framing-
am risk (20%) or with diabetes mellitus, to
nsure that the results were not driven by patients
lready recommended for statin therapy.
This study was approved by the St. Francis
ospital Institutional Review Board, and all par-
icipants provided written informed consent.
Post hoc analysis. We analyzed the initial cohort
tratified to family history. There were 546 individ-
als with a positive family history for premature
AD. This was defined as 1 first-degree relative
ith premature CAD: men before the age of 55
ears and women before the age of 65 years. We
hen assessed whether the differences in treatment
odalities led to a difference in cardiovascular
utcome in individuals, depending of the presence
r absence of a positive family history for premature
AD.
Statistical analysis. We assessed differences in base-
line characteristics between individuals with pres-
ence or absence of a positive family history for
premature CAD by using chi square tests (in case of
proportions), Student t tests (in case of continuous
normally distributed data), or Wilcoxon signed rank
test (in case of continuous not-normally distributed
data).
Kaplan-Meier curves were used to estimate the
probability of experiencing a clinical event for either
individuals receiving active treatment or placebo
and tested differences between curves with log-rank
test. Cox proportional hazards analyses were used to
correct for differences between the treatment and
the placebo groups where appropriate. Also, we
performed an interaction test for family history and
efficacy of treatment via Cox proportional hazards
analyses.
All hypothesis tests were conducted with an
alpha level of 0.05 and were 2 tailed, and all
outcomes were analyzed on the basis of intention to
treat.
R E S U L T S
Population. The flow of participants in this trial has
een described in detail elsewhere (17). Table 1
hows the baseline characteristics of all randomizedarticipants. We compared baseline characteristics
f the treated group with the placebo group, strat-
fied for either presence or absence of a positive
amily history for premature CAD.
Within both strata of individuals with either a
ositive or a negative family history, all variables
ere well matched. In the stratum of individuals
ith a positive family history, triglyceride levels
ere lower at baseline in the treated group com-
ared with the placebo group (1.3 [interquartile
ange: 0.9 to 2.0] mmol/l vs. 1.5 [interquartile
ange: 1.0 to 2.1] mmol/l; p  0.010). In the
tratum of individuals with a negative family his-
ory, in the treated group, more individuals had an
Figure 1. All Cardiovascular Events in Individuals With a
Positive Family History
Kaplan-Meier survival curves for all cardiovascular events in individu
a positive family history for premature CAD. CAD  coronary artery
Table 2. Outcome Rate in Individuals With a Positive and a Neg
History for Premature CAD, Divided by Treatment
Positive Family History
Ne
Placebo
(n  280)
Treated
(n  263)
Place
(n  2
Primary outcome
All CV events 35 (12.5) 19 (7.2)* 16 (6
Myocardial infarction 13 (4.6) 5 (1.9) 3 (1
Coronary revascularization 17 (6.0) 13 (4.9) 10 (4
Stroke 0 (0) 1 (0.4) 1 (0
Peripheral vascular surgery 5 (1.8) 0 (0)* 2 (0
Secondary outcome
All coronary events 30 (10.7) 18 (6.8) 13 (5
CV events after 90 days 31 (11.0) 18 (6.8)* 14 (5
Categorical values are n (%). All coronary events included nonfatal myocardia
death, and surgical or percutaneous coronary revascularization procedures. *p
CAD  coronary artery disease; CV  cardiovascular.als with
disease;ative Family
gative Family
History
bo
36)
Treated
(n  226)
.8) 15 (6.6)
.3) 4 (1.8)
.2) 9 (4.0)
.4) 1 (0.4)
.8) 1 (0.4)
.5) 13 (5.7)
.9) 13 (5.7)
l infarction, coronary
0.05 versus placebo.CI  conﬁdence interval; HR hazard ratio.
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256intermediate Framingham risk (49.1% [n  111]
vs. 36.0% [n  85]; p  0.004), and fewer individ-
als had a high Framingham risk (8.0% [n 18] vs.
6.5% [n  39]; p  0.005) compared with the
lacebo group. Medication use and risk factor
resence were similar in all groups.
Furthermore, individuals with a positive family
istory had overall a higher incidence of hyperten-
ion (34.6% [n  188] vs. 27.1% [n  125]; p 
.010), total cholesterol levels (5.9 0.9 mmol/l vs.
.7  0.9 mmol/l; p  0.0001), and low-density
lipoprotein (LDL) cholesterol levels (3.9  0.8
mmol/l vs. 3.7  0.8 mmol/l; p  0.0001) com-
All Cardiovascular Events in Individuals With a
Family History
ier survival curves for all cardiovascular events in individuals with
family history for premature CAD. Abbreviations as in Figure 1.
All Coronary Events in Individuals With a
amily History
ier survival curves for all coronary events in individuals with a
mily history for premature CAD. Abbreviations as in Figure 1.pared with individuals with a negative family his-
tory. No gender differences were present.
During the course of the trial, there were no
significant differences between the treated group
and the placebo group in both strata in blood
pressure, body mass index, and glucose levels. Total
cholesterol and LDL cholesterol levels did differ
between treated and untreated individuals in both
strata. However, in the treated individuals, those
with a positive or a negative family history did not
differ in terms of total cholesterol and LDL cho-
lesterol levels. This also applied to the placebo-
treated individuals.
Compliance averaged 85% for atorvastatin or its
matching placebo, 88% for vitamins C and E or
their matching placebos, and 79% for aspirin. Con-
versely, under the direction of their private physi-
cians, 14% of subjects assigned to the control arm
were initiated on a statin without an antecedent
cardiovascular event.
Primary outcome. After a median follow-up of 4.3
years, in the stratum of individuals with a positive
family history for premature CAD, 7.2% (n  19)
in the treated group versus 12.5% (n  35) in the
placebo group had a cardiovascular event (p  0.039)
(Table 2). The events in both the treated and the
placebo groups consisted mostly of coronary revas-
cularizations (n  13 and n  17, respectively) and
myocardial infarctions (n  5 and n  13, respec-
tively). In the stratum of individuals with a negative
family history for premature CAD, 6.6% (n  15)
in the treated group versus 6.8% (n  15) in the
placebo group had a cardiovascular event (p 0.95)
(Table 2).
Coronary events. In the stratum of individuals with
positive family history, 6.8% (n  18) in the
reated group versus 10.7% (n  30) in the placebo
roup had a coronary event (p  0.11) (Table 2).
hereas in the stratum of individuals with a
egative family history, 5.7% (n 13) in the treated
group versus 5.5% (n  13) in the placebo group
ad a coronary event (p  0.91) (Table 2).
Cardiovascular events after >90 days. In the stratum
f individuals with a positive family history, 6.8%
n 18) in the treated group versus 11.0% (n 31)
in the placebo group had a cardiovascular event
after 90 days (p  0.048) (Table 2). In the
stratum of individuals with a negative family his-
tory, 5.7% (n 13) in the treated group versus 5.9%
(n  14) in the placebo group had a cardiovascular
event after 90 days (p  0.93) (Table 2).
Furthermore, Cox proportional hazards analysesFigure 2.
Negative
Kaplan-MeFigure 3.
Positive F
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257with a positive family history had a 45% reduction
in cardiovascular events (hazard ratio [HR]: 0.55;
95% confidence interval [CI]: 0.31 to 0.97; p 
0.040) (log-rank  0.037, Fig. 1), whereas this was
ot observed in individuals with a negative family
istory (HR: 1.04; 95% CI: 0.51 to 2.13; p 
.912) (log-rank  0.912, Fig. 2). These observa-
ions were also true for coronary events and cardio-
ascular events after 90 days (Figs. 3, 4, 5 and 6).
his reduction in cardiovascular events in individ-
als with a positive family history resulted in a
umber needed to treat of 18.9.
We assessed Cox proportional hazards analyses
o evaluate the different components of the pri-
ary outcome (Fig. 7). Figure 7 shows the
reatment effect in individuals with a positive
amily history assessed by HR and 95% CI in the
rimary outcome, its components, and the sec-
ndary outcomes. For the primary outcome, the
omponents stroke and peripheral vascular sur-
ery are not included in Figure 7, since the low
vent rates resulted in erratic effect estimates. We
ound that the effect of treatment was mainly
riven by the reduction in myocardial infarctions
HR: 0.40; 95% CI: 0.14 to 1.14; p  0.083).
orrection for triglycerides at baseline, which
as the only significantly different variable be-
ween the treatment and placebo groups for
ndividuals with a positive family history did not
hange the results (HR: 0.56; 95% CI: 0.32 to
.99; p  0.045). Correction for other possible
onfounders did not change these results. Fur-
hermore, excluding individuals already recom-
ended for statin therapy (e.g., individuals with
high Framingham risk or diabetes mellitus)
ven increased the effect of treatment (HR: 0.46;
5% CI: 0.24 to 0.87; p  0.016). The results of
he interaction test between treatment group and
amily history for the primary outcome showed
imilar results as for the stratified analysis. How-
ver, it did not reach statistical significance,
ossibly due to the low event rate (HR: 0.42; 95%
I: 0.17 to 1.04; p  0.06).
D I S C U S S I O N
In this post hoc analysis, we show that treatment
with atorvastatin 20 mg, vitamin C 1 g, and vitamin
E 1,000 U in asymptomatic individuals with a
positive family history for premature CAD and a
igh CCS resulted in a 45% reduction in cardio-
ascular events. These data suggest that individuals
ith a positive family history for premature CADnd a high CCS do benefit from preventive treat-
ent. Interestingly, excluding individuals already
ecommended for statin therapy even increased the
ffect of treatment.
Interpretation of results. Preventive treatment in
these individuals is still a matter of debate (23). If
we assume an important hereditary component, not
all relatives will be at risk to the same extent.
Therefore, treatment should be tailored to those
individuals with the highest chance of future clini-
cal manifestations of CVD. In this post hoc anal-
Figure 4. All Coronary Events in Individuals With a
Negative Family History
Kaplan-Meier survival curves for all coronary events in individuals w
negative family history for premature CAD. Abbreviations as in Figu
Figure 5. All Cardiovascular Events After 90 Days in Individuals
Positive Family History
Kaplan-Meier survival curves for all cardiovascular events after 90 d
individuals with a positive family history for premature CAD. Abbreith aWith a
ays in
viationsas in Figure 1.
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258ysis, this proved to be those with elevated CCS,
which might reflect subclinical atherosclerotic vas-
cular disease.
So far, no randomized controlled study has
shown any beneficial effect of preventive treat-
ment in individuals with elevated CCS. Yet, the
latest American College of Cardiology Founda-
tion/American Heart Association guidelines on
cardiovascular risk state that measuring CCS is
reasonable for cardiovascular risk assessment in
asymptomatic individuals (15). This was ex-
tended by the Appropriate Use Criteria For
Cardiac Computed Tomography guidelines,
which states that measuring CCS is also appro-
priate in low-risk patients in whom a family
history of premature CAD was present (14).
Surprisingly, although measuring CCS is recom-
mended, no evidence existed that treatment of
individuals with elevated CCS reduces cardiovascu-
lar risk. In these guidelines, this lack of evidence
was already recognized.
The only RCT investigating the treatment of
such a population is the St. Francis Heart study
(17), in which we have performed a post hoc
analysis. The St. Francis Heart study shows a
33% reduction in events, but this did not reach
statistical significance (p  0.08). According to
the authors, this might have been due to lack of
power (17). On the other hand, a subgroup
analysis of this study showed that treatment of
individuals with CCS above 400 Agatston Units
All Cardiovascular Events After 90 Days in Individuals With a
Family History
ier survival curves for all cardiovascular events after 90 days in
with a negative family history for premature CAD. Abbreviations
e 1.was beneficial. In this subgroup analysis, the wevent rate in the treated group was 8.7% versus
15.0% in the placebo group, which represents an
event reduction of 40% (17).
Other studies investigating this issue have only
focused on progression of CCS and have shown
conflicting results (24 –27). These inconsistencies
have been addressed by Henein and Owen (28) in
a recent meta-analysis. These authors concluded
that statin therapy did not reduce CCS progres-
sion, but did attenuate luminal CAD narrowing.
A possible explanation lies in the fact that lumi-
nal narrowing represents soft tissue inflammatory
pathology, whereas increased CCS represents
tissue mineralization, which is unlikely to regress
with statins.
Our findings are in line with those recently
obtained in the JUPITER (Justification for the Use
of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin) trial. In this study,
asymptomatic individuals with elevated high-
sensitivity C-reactive protein levels were treated
with rosuvastatin or placebo. Rosuvastatin therapy
resulted in a significant reduction of cardiovascu-
lar events, which, according to a subgroup analysis,
was most evident in those with a positive family
history (29).
Consideration of limitations. The possible limita-
ions of our study merit discussion. This study
ncompasses all inherent limitations of a post hoc
nalysis, most importantly, the loss of random-
zation and power. Fortunately, in this post hoc
nalysis, randomization was maintained to some
xtent. In those with a positive family history,
nly triglyceride levels were significantly higher
n the placebo group compared with the treated
roup. However, this must have been due to
hance, since randomization was done by con-
ealment of allocation and information on family
istory, or else triglyceride levels could not have
nfluenced this. After correction for triglyceride
evels, results remained the same. In terms of the
nteraction test between family history and treat-
ent, we found a similar effect as we did in the
tratified analysis of individuals with a positive
amily history. The test for interaction was nearly
ignificant (p  0.06), which we believe is due to
ack of power, based on the rather low number of
vents. Also, the inclusion of revascularizations is
relative soft outcome; however, the effect of
reatment was more pronounced in reducing
yocardial infarctions.
Furthermore, we emphasize that this populationFigure 6.
Negative
Kaplan-Me
individualsas selected as those with CCS above the 80th
r; o
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259percentile. The results should not be extrapolated to
patients with lower CCS; we believe that further
study is needed in this area.
Recent studies have shown no additional effects
of vitamin supplementation on cardiovascular
events (30,31). Therefore, we conclude that the
difference in cardiovascular events in the St. Francis
Heart study RCT must have been based on the
effect of atorvastatin.
C O N C L U S I O N S
Preventive treatment of asymptomatic individuals
with a positive family history for premature CAD
and elevated CCS might reduce cardiovascular
Figure 7. HR of the Different Outcomes
HR of the primary outcome, its components, and secondary outcom
mature CAD compared with the placebo group. CV  cardiovascula2007;99:825–9. 60–6.for future guidelines concerning primary preven-
tion in individuals with a positive family history
for premature CAD. Although much controversy
exists with regard to treatment of those with
elevated CCS in primary prevention, preventive
treatment of individuals with a positive family
history for premature CAD and a high CCS
could indeed be beneficial in terms of cardiovas-
cular outcome.
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